IP Library Granted Patent US 10,124,328
Granted Patent B2
US 10,124,328 · App. 15/407,240 · Granted Nov 13, 2018

Separation method and separation matrix

Inventors: Jesper Hansson (Uppsala, SE); Gustav Rodrigo (Uppsala, SE); Tobias E Soderman (Uppsala, SE)
Assignee: GE Healthcare BioProcess R&D AB
B01J39/26B01D15/1864B01D15/34B01D15/361B01D15/362B01D15/3809B01J20/24B01J20/261B01J20/265B01J20/267B01J20/286B01J20/289B01J20/28014B01J20/28033B01J20/3085B01J20/3212B01J20/3278B01J20/3282C07H1/08C07K1/22B01J2220/80G01N2030/8827Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,124,328
App. No.
15/407,240
Granted
Nov 13, 2018
Kind
B2
Abstract

The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH 2 ═CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.

Claims (30)

1. A separation matrix comprising a solid support and copolymer chains bound to said solid support, wherein said copolymer chains comprise units derived from

a) a first monomer of structure CH 2 ═CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate group and

b) an N-vinyl amide,

wherein the molar ratio of the units derived from the first monomer to the units derived from the second non-charged monomer is 0.05 to 5.

2. The separation matrix of claim 1 , wherein said first monomer is selected from a group consisting of vinyl sulfonate and allyloxyhydroxypropyl sulfonate.

3. The separation matrix of claim 1 , wherein said first monomer is vinyl sulfonate.

4. The separation matrix of claim 1 , wherein said second non-charged monomer is selected from a group consisting of N-vinyl pyrrolidone, N-vinyl caprolactam, N-vinyl formamide and N-vinyl acetamide.

5. The separation matrix of claim 1 , wherein said second non-charged monomer is N-vinyl pyrrolidone.

6. The separation matrix of claim 1 , wherein in said copolymer chains the molar ratio of the units derived from the first monomer to the units derived from the second non-charged monomer is 0.5 to 2.

7. The separation matrix of claim 1 , having an ion capacity of 20-200 micromol/mL and a pore size corresponding to a KD value of 0.1-0.8, measured with dextran of Mw 110 kDa as the probe molecule.

8. The separation matrix of claim 7 , wherein the ion capacity of said matrix is 30-70 micromol/mL.

9. The separation matrix of claim 1 , wherein the total content of said copolymer chains in the matrix is 2-80 mg/ml.

10. The separation matrix of claim 1 , wherein said solid support comprises a polysaccharide having has a pore size corresponding to a KD value of 0.5-0.9, measured with dextran of Mw 110 kDa as the probe molecule.

11. The separation of claim 1 , wherein said solid support comprises agar or agarose.

12. The separation matrix of claim 11 , wherein the total content of said copolymer chains in the matrix is 2-20 mg/ml.

13. The separation matrix of claim 1 , wherein said solid support comprises crosslinked agarose and wherein said separation matrix has a pore size corresponding to a KD value of 0.2-0.6, measured with dextran of Mw 110 kDa as the probe molecule.

14. A separation matrix comprising a solid support and copolymer chains bound to said solid support, wherein said copolymer chains comprise units derived from

a) a first monomer selected from a group consisting of vinyl sulfonate and allyloxyhydroxypropyl sulfonate and

b) a second non-charged monomer selected from the group consisting of N-vinyl pyrrolidone, N-vinyl caprolactam, N-vinyl formamide and N-vinyl acetamide,

wherein in said copolymer chains the molar ratio of the units derived from the first monomer to the units derived from the second non-charged monomer is 0.5 to 2.

15. The separation matrix of claim 14 , having an ion capacity of 30-70 micromol/mL and a pore size corresponding to a KD value of 0.1-0.8, measured with dextran of Mw 110 kDa as the probe molecule.

16. The separation matrix of claim 14 , wherein the total content of said copolymer chains in the matrix is 2-20 mg/ml.

17. The separation matrix of claim 14 , wherein said solid support agar or agarose having has a pore size corresponding to a KD value of 0.5-0.9, measured with dextran of Mw 110 kDa as the probe molecule.

18. The separation matrix according to claim 14 , wherein said solid support comprises crosslinked agarose and wherein said separation matrix has a pore size corresponding to a KD value of 0.2-0.6, measured with dextran of Mw 110 kDa as the probe molecule.

19. The separation matrix of claim 14 , wherein said solid support comprises crosslinked agarose and wherein said separation matrix has a pore size corresponding to a KD value of 0.2-0.6, measured with dextran of Mw 110 kDa as the probe molecule.

20. A separation matrix comprising a solid support and copolymer chains bound to said solid support having an ion capacity of 30-70 micromol/mL and a pore size corresponding to a KD value of 0.1-0.8, measured with dextran of Mw 110 kDa as the probe molecule, wherein said copolymer chains comprise units derived from

a) vinyl sulfonate and b) N-vinyl pyrrolidone,

wherein in said copolymer chains the molar ratio of the units derived from the first monomer to the units derived from the second non-charged monomer is 0.5 to 2,

wherein the total content of said copolymer chains in the matrix is 2-20 mg/ml, and

wherein said solid support comprises crosslinked agarose and wherein said separation matrix has a pore size corresponding to a KD value of 0.2-0.6, measured with dextran of Mw 110 kDa as the probe molecule.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: HANSSON, JESPER; RODRIGO, GUSTAV; SODERMAN, TOBIAS E.
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 045071/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 045473/0227 →
Priority Claims (1)
SE 1250413 · Apr 25, 2012 · national
Continuity (2)
Continuation 14396207
Related Publication 20170120232A1 · May 4, 2017
Cited By (1)
US 12,434,218